据外媒报道，22日制药公司百健(Biogen)发布声明称，经过临床试验和数据分析，该公司研发的药物“aducanumab”对治疗轻度认知障碍和阿尔茨海默症早期症状有效，将提请美国食品药品管理局(FDA)批准上市。

　　Drug company Biogen said on Tuesday that it would ask the Food and Drug Administration to approve an experimental drug, aducanumab, to treat people with mild cognitive impairment and the earliest signs of Alzheimer's disease.

　　Alzheimer：['ælz'ɛmɚ]n. 阿尔茨海默症　　

　　Patients who received aducanumab experienced significant benefits on measures of cognition and function such as memory, orientation and language.

　　英国广播公司（BBC）报道指出，这一消息多少有些令人感到意外。